Core Viewpoint - The current market is in a bull phase, with significant losses reported among short sellers in commodity and stock index futures. The article suggests that the most certain investment opportunities in a bull market are either in leading sectors or in severely undervalued stocks [2]. Group 1: Investment Opportunities - The article emphasizes that low-priced stocks tend to be driven up to reasonable levels during a bull market, indicating that underperforming sectors may see substantial gains due to ongoing liquidity and policy support [2]. - The upcoming major meetings are expected to enhance expectations for "stabilizing growth," which may provide considerable policy space for undervalued industries [2]. Group 2: ETF Analysis - The article utilizes the net value percentile calculation method to assess which sectors are currently in a state of severe undervaluation [3]. - A table is provided showing various ETFs, their net value percentiles since 2023 and 2024, and their performance in 2025, highlighting sectors like photovoltaic, alcohol, and real estate [7]. Group 3: Sector-Specific Insights - The photovoltaic sector is identified as particularly undervalued, with ETFs like the photovoltaic ETF (515790.SH) and new energy ETF (516160.SH) showing significant declines. The sector's performance is closely tied to government policies aimed at stabilizing growth [9][10]. - The alcohol sector, particularly the alcohol ETF (512690.SH), is also noted for being in a state of decline, with a lack of clear catalysts for recovery until consumer data improves [20][21]. - The real estate sector shows signs of divergence, with the real estate ETF (159707.SZ) experiencing intermittent policy-driven rallies but ultimately returning to lower levels [25][26]. Group 4: Medical and Pharmaceutical Sector - The medical and pharmaceutical sectors are highlighted as being collectively undervalued, with various ETFs like the biopharmaceutical ETF (159859.SZ) showing potential for recovery due to recent policy shifts regarding procurement practices [33][35]. - The medical ETF (512170.SH) is also mentioned as being in a relatively low valuation position, with a modest performance outlook [39]. Group 5: Commodity and Chemical Sectors - The coal sector has seen a significant price drop but is experiencing a rebound due to rising prices in coking coal and coke futures, with the coal ETF (515220.SH) reflecting this trend [43][45]. - The chemical sector is noted for its broad product range and recent price increases in lithium carbonate, with the chemical ETF (159870.SZ) positioned as relatively undervalued [49][54]. Conclusion - The article concludes that sectors such as chemicals, biopharmaceuticals, medical, alcohol, and photovoltaic are currently in a state of severe undervaluation, presenting potential investment opportunities for discerning investors [56].

Group 1: Biovaccine ETFs - There are two ETFs named Biovaccine ETF, one managed by Penghua Fund tracking the Guozhen Vaccine and Biotechnology Index, consisting of 50 companies with an average market capitalization of approximately 53.9 billion yuan [1][3] - The second Biovaccine ETF is managed by Harvest Fund, tracking the Zhongzheng Vaccine and Biotechnology Index, which includes up to 50 companies involved in vaccine research and production, with an average market capitalization of about 22 billion yuan [3][5] - The two indices share 19 overlapping constituent stocks, with the Guozhen index having 31 unique stocks and the Zhongzheng index having 24 unique stocks [5][6] - In terms of past performance, the Zhongzheng Vaccine and Biotechnology Index has outperformed the Guozhen index over one, three, and five years, with a notably higher increase in the past year [6][7] Group 2: Biopharmaceutical ETFs - There are two ETFs named Biopharmaceutical ETF, one managed by Tianhong Fund tracking the Guozhen Biopharmaceutical Index, which includes the top 30 companies based on market capitalization and liquidity, with an average market capitalization of around 45.2 billion yuan [11][13] - The second Biopharmaceutical ETF is managed by Guotai Fund, tracking the Zhongzheng Biopharmaceutical Index, which selects companies providing cell therapy, gene sequencing, and other biopharmaceutical services, with an average market capitalization of approximately 71.9 billion yuan [13][15] - The two indices have 18 overlapping constituent stocks, with each index having 12 unique stocks [15][16] - The Zhongzheng Biopharmaceutical Index has consistently outperformed the Guozhen index over one, three, and five years, while the Guozhen index exhibits higher annualized volatility [15][17]

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETFs, with Tianhong Innovative Drug ETF (517380) leading the industry with a 1.89% increase and a total trading volume of 4.6489 million yuan on July 23, 2025 [2] - The Tianhong Innovative Drug ETF has seen a cumulative increase of 3.93% over the past week, indicating positive momentum in the sector [2] - The Biopharmaceutical ETF (159859) also showed a 1.50% increase with a trading volume of 40.8703 million yuan, reflecting strong investor interest [2] Group 2 - The Biopharmaceutical ETF (159859) has achieved a 2.84% increase over the past week, ranking first among comparable funds, with an average daily trading volume of 110 million yuan [3] - The Biopharmaceutical ETF has experienced a significant growth of 543 million yuan in scale over the past year, indicating robust demand [3] - Guotai Junan Securities continues to recommend the innovative drug sector, citing improvements in both domestic and overseas markets, with new insurance directories supporting innovative drug development [3] Group 3 - The collaboration between stable operation of medical insurance funds and optimized centralized procurement policies is positively impacting the innovative drug industry, enhancing patient accessibility and market demand [4] - Recent trends show that multiple pharmaceutical companies are successfully launching innovative drugs overseas, validating China's R&D capabilities [4] - The Tianhong Innovative Drug ETF (517380) is noted as the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Select 50 Index, providing comprehensive coverage of A-shares and Hong Kong stocks [4]

Core Viewpoint - The Chinese pharmaceutical sector is experiencing positive momentum due to supportive government policies aimed at fostering the development of innovative drugs, which is expected to enhance the industry's growth and investment opportunities [3]. Policy Support - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including increased R&D support, inclusion in basic medical insurance, and improved clinical application [3]. - The introduction of the 2025 basic medical insurance directory and commercial health insurance innovative drug directory aims to enhance the multi-tiered medical security system, addressing payment challenges for high-value innovative drugs [3]. Market Outlook - The year 2025 is anticipated to be significant for domestic innovative drugs entering international markets, following a seven-year transition from generic to innovative drugs since the "4+7" procurement policy was implemented in 2018 [3]. - The pharmaceutical sector is expected to see a rise in sentiment and valuation due to ongoing policy support, improved payment mechanisms, enhanced R&D capabilities, and the integration of AI technologies [4]. AI Integration - AI is projected to comprehensively empower the pharmaceutical industry, improving efficiency in drug development, production, and medical services [4]. - The implementation plan for the digital transformation of the pharmaceutical industry aims for comprehensive coverage of intelligent transformation by 2030 [4]. Investment Opportunities - The innovative drug ETFs, such as Guotai (517110), are highlighted as worthy of continued attention, alongside other ETFs focused on the entrepreneurial and biopharmaceutical sectors [4].

消息面上，2025年6月30日生物医药产业资本对接会成功举办，促进产融合作。此外，6月24日，市药品 监督管理局在宝山高新区举办第三期生物医药产品"注册讲堂"，聚焦无源/有源器械及体外诊断试剂检 测与临床评价要点，为80余家医疗器械企业提供政策指导。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相 匹配的产品。基金有风险，投资需谨慎。 （文章来源：每日经济新闻） 东莞证券指出，医药生物板块近期迎来回调，此前涨幅较大的创新药相关产业链和减肥药板块跌幅居 前。目前国内创新药公司经过多年研发投入，陆续进入收获期，创新药领域近期利好频出，新药出海授 权金额不断创新高，创新药业务开始为创新药企业贡献业绩。SW医药生物行业近期下跌5.05%，跑输 同期沪深300指数约6.43个百分点，三级细分板块全部录得负收益，其中医疗耗材和医院板块跌幅较 少，化学制剂和线下药店板块跌幅居前。行业估值有所下降，目 ...

每经编辑｜赵云 创新药板块6月12日发力走强，创新药ETF国泰（517110）开盘逆市上涨，全天收涨4.39%。生物医药 ETF（512290）收涨2.02%。 | 代码 | 名称 | 涨跌幅 * | | --- | --- | --- | | 517110 | 创新药ETF国泰 | 4.39% | | 512290 | 生物医药ETF | 2.02% | 来源：Wind 消息面，国产创新药BD利好频传。创新药BD（Business Development，商务拓展）在医药行业中主要指 通过License-in（授权引进）和License-out（授权输出）等交易模式，实现创新药产品的商业化合作。近 年来，随着中国创新药企的崛起，BD尤其是License-out（对外授权）成为药企获取现金流、拓展国际 市场的重要途径。 继三生制药与辉瑞达成SSGJ-707重磅授权、石药集团宣布潜在的三项大型海外授权交易后，中国生物 制药也发出预告，近期将有一笔标志性的重磅对外授权交易落地。创新药板块重要成份股荣昌生物也在 与多家跨国公司洽谈BD。荣昌生物的BD是市场关注的焦点，泰它西普传闻BD金额可能破200亿美元， 去年曾 ...

Core Viewpoint - The ETF market is experiencing a significant disparity, with some ETFs showing high trading volumes while many others face low liquidity and potential liquidation risks [1][5]. Group 1: ETF Market Performance - On June 10, certain ETFs like the Hong Kong Innovative Drug ETF and the Hang Seng Technology ETF had trading volumes exceeding 10 billion yuan, while over 500 ETFs had trading volumes below 10 million yuan [1]. - A total of 513 ETFs had trading volumes below 10 million yuan on June 10, with 129 ETFs trading below 1 million yuan [4][3]. - The concentration of market resources is evident, with the top ten ETFs accounting for nearly 40% of the total market size, while over 20% of ETFs have sizes below 100 million yuan [5]. Group 2: Liquidity and Risk Factors - The number of ETFs with net asset values below 50 million yuan has been increasing, indicating higher liquidity and liquidation risks [2][5]. - Analysts emphasize that low liquidity can lead to a vicious cycle where smaller ETFs struggle to attract investors, further diminishing their liquidity and increasing the likelihood of liquidation [5]. Group 3: Strategies to Enhance Liquidity - Fund companies are increasingly adding liquidity providers to improve ETF trading efficiency and attract more investors [7][8]. - The introduction of liquidity providers aims to reduce bid-ask spreads and enhance trading volumes, which can lead to scale effects [7][8]. - Improving liquidity is seen as essential for enhancing investor experience and attracting long-term capital [9]. Group 4: Recommendations for ETF Companies - Companies are advised to focus on product differentiation to avoid homogeneous competition, including not launching new ETFs in crowded index spaces and innovating product offerings [12][13]. - Providing value-added services, such as investment strategy reports and interactive investor engagement, can enhance investor experience and loyalty [13][14]. - Companies should also consider lowering management fees through increased ETF scale and exploring new themes like ESG and digital economy ETFs to meet diverse investor needs [14].

Core Insights - On June 9, 2025, a total of 212 ETF funds experienced net inflows, while 390 funds saw net outflows, indicating a significant disparity in investor sentiment towards different ETFs [1] - The top five ETFs with net inflows exceeding 100 million yuan included the SSE 50 ETF, Credit Bond ETF, Ten-Year Treasury ETF, CSI 300 ETF, and SSE Corporate Bond ETF, with inflows of 1.48 billion yuan, 856.5 million yuan, 654 million yuan, 615 million yuan, and 550 million yuan respectively [1][3] - Conversely, 17 ETFs had net outflows exceeding 100 million yuan, with the ChiNext ETF, Hang Seng Internet ETF, Short-term Bond ETF, Military Industry ETF, and Pharmaceutical ETF leading the outflows, totaling 359 million yuan, 331 million yuan, 287 million yuan, 285 million yuan, and 214 million yuan respectively [1][5] Inflow and Outflow Analysis - A total of 110 ETFs have seen consecutive net inflows, with the top performers being the Hong Kong Stock Connect Dividend ETF (29 days), Soybean Meal ETF (27 days), High Dividend ETF (26 days), SSE 180 Index Fund (23 days), and Credit Bond ETF Dachen (23 days), accumulating inflows of 445 million yuan, 61.69 million yuan, 171.34 million yuan, 140 million yuan, and 3.16 billion yuan respectively [1][7] - In contrast, 202 ETFs have experienced consecutive net outflows, with the leading ones being the Biopharmaceutical ETF (32 days), Innovative Drug ETF (27 days), Dividend Value ETF (26 days), Hang Seng Consumer ETF (24 days), and Traditional Chinese Medicine ETF (23 days), resulting in outflows of 556 million yuan, 3.29 billion yuan, 213 million yuan, 303 million yuan, and 262 million yuan respectively [1][8] Recent Trends - Over the past five days, 66 ETFs have recorded cumulative net inflows exceeding 100 million yuan, with the Short-term Bond ETF, Ten-Year Treasury ETF, Credit Bond ETF, Corporate Bond ETF, and SSE Corporate Bond ETF leading with inflows of 3.42 billion yuan, 3.37 billion yuan, 2.48 billion yuan, 2.29 billion yuan, and 2.19 billion yuan respectively [1][8] - Conversely, 86 ETFs have seen cumulative net outflows exceeding 100 million yuan, with the ChiNext ETF, Hang Seng Internet ETF, Hang Seng Medical ETF, Hong Kong Innovative Drug ETF, and East Financial Treasury ETF leading the outflows, totaling 1.82 billion yuan, 971 million yuan, 825 million yuan, 763 million yuan, and 583 million yuan respectively [1][8]

此外，国证生物医药指数(399441.SZ)上涨2.05%，该指数成分股中，迪哲医药-U与康泰生物上涨超 6%，泰格医药与复星医药等4只个股上涨超4%，智飞生物与凯莱英上涨近4%。相关ETF方面，生物医 药ETF(159859)截至发稿上涨1.91%，成交额为8999.98万元，暂居同标的第一名。 6月9日，A股、港股生物医药板块再度大涨，涨幅领先。恒生沪深港创新药精选50指数(HSSSHID.HK) 上涨3.74%，该指数成分股中，金斯瑞生物科技上涨超16%，诺诚健华-U上涨超14%，诺泰生物上涨超 12%。 相关ETF方面，创新药ETF天弘(517380)截至发稿涨超4%，成交额为1633.7万元，实时溢价率为 0.01%。 创新药ETF天弘(517380)是全市场唯一一只跟踪恒生沪深港创新药精选50指数的ETF产品，该指数覆盖 了沪、深、港三地创新药龙头，十大权重股包括百济神州、药明康德、恒瑞医药、泰格医药等细分领域 龙头，创新药"浓度"极高。同时，该ETF及联接基金（A类：014564，C类：014565）采用量化指标优 化。 生物医药ETF（159859）紧密跟踪国证生物医药指数（399441.SZ ...

Core Insights - On June 4, 2025, a total of 176 ETFs experienced net inflows, while 377 ETFs saw net outflows, indicating a significant disparity in investor sentiment towards different funds [1] - Among the ETFs with net inflows exceeding 100 million yuan, notable funds included Short-term Bond ETF (511360.SH) with 1.121 billion yuan, Innovation ETF (562570.SH) with 781 million yuan, and Sci-tech Chip ETF (588200.SH) with 765 million yuan [1][3] - Conversely, 12 ETFs had net outflows exceeding 100 million yuan, with the leading outflow being from the ChiNext ETF (159915.SZ) at 650 million yuan, followed by Gold ETF (518880.SH) at 368 million yuan [1][5] Inflow and Outflow Analysis - The top five ETFs with significant net inflows included Short-term Bond ETF, Innovation ETF, Sci-tech Chip ETF, Credit Bond ETF (511190.SH), and Yinhua Daily ETF (511880.SH), with inflows of 1.121 billion yuan, 781 million yuan, 765 million yuan, 683 million yuan, and 546 million yuan respectively [1][3] - The top five ETFs with substantial net outflows were ChiNext ETF, Gold ETF, Hong Kong Innovative Drug ETF (513120.SH), Hang Seng Medical ETF (513060.SH), and CSI 1000 ETF (512100.SH), with outflows of 650 million yuan, 368 million yuan, 318 million yuan, 311 million yuan, and 271 million yuan respectively [1][5] Recent Trends - A total of 102 ETFs have seen continuous net inflows, with the leading funds being Trading Money ETF (511690) for 28 days, Hong Kong Stock Connect Dividend ETF (513530) for 26 days, and Soybean Meal ETF (159985) for 24 days, accumulating inflows of 26.49 million yuan, 416.4 million yuan, and 54.71 million yuan respectively [1][7] - In contrast, 193 ETFs have experienced continuous net outflows, with the most significant being Biopharmaceutical ETF for 29 days, Innovative Drug ETF for 24 days, and Dividend Value ETF for 23 days, with outflows of 479 million yuan, 3.02 billion yuan, and 207 million yuan respectively [1][8] Five-Day Performance - Over the past five days, 53 ETFs recorded net inflows exceeding 100 million yuan, with the highest being Short-term Bond ETF at 3.625 billion yuan, followed by Credit Bond ETF at 2.543 billion yuan [1][8] - Conversely, 61 ETFs had net outflows exceeding 100 million yuan, with the largest outflow from Hang Seng Medical ETF at 1.143 billion yuan, followed by ChiNext ETF at 926 million yuan [1][8]